NVAX

7.4703.24%
MG

Margaret G. McGlynn

Independent Vice Chairman of the Board of Directors

Ms. Margaret G. McGlynn, also known as Margie, R.Ph., serves as a Director of Amphion Innovations and VennWorks. Ms. McGlynn has been an Independent Director of Novavax, Inc. since December 5, 2020 and served as its Chairperson since March 10, 2025 until 2026 and serves as vice chairman of the board from 2026. Ms. McGlynn served as the Chief Executive Officer and President of International AIDS Vaccine Initiative Inc. from July 2011 to September 2015. She was President, U.S. Hospital and Specialty Products Division. Ms. McGlynn served as the President of Merck Vaccines and Infectious Diseases at Merck & Co., Inc. from 2005 to August 2009. She holds prior leadership of the Global Vaccine and Infectious Disease Division of Merck & Co., Inc. She had global responsibilities for the vaccines business and infectious diseases franchise including Merck & Co's Sanofi-Pasteur joint venture. In her nearly three decades at Merck, Ms. McGlynn held several leadership roles focused on marketing, sales and managed care activities for Merck’s portfolio of medicines. She served as the President of Merck Vaccines of Merck & Co. Inc. since September 1, 2005. Ms. McGlynn has significant leadership experience in the pharmaceutical industry, including her service as a senior executive of Merck where she led commercialization across several therapeutic areas and geographies and managed large organizations. She joined Merck in 1983 and served in a variety of marketing, sales and managed care roles. She served as the President of US Human Health Division of Merck & Co., Inc. from January 2003 to September 1, 2005 and was responsible for one of the two prescription drug divisions comprising USA Human Health (USHH) and the Managed Care Group of USHH. She served as an Executive Vice President of Customer Marketing and Sales, USHH at Merck & Co., Inc. from August 2001 to 2002 and served as a Senior Vice President of Worldwide Human Health Marketing from November 1998 to 2001. She is a Board Member of University at Buffalo Foundation EDUCATION. She served as a Senior Vice President of Health and Utilization Management at Medco Health Solutions, Inc., a wholly-owned subsidiary of Merck & Co., Inc. since August 1995. She serves as the President and Chair of the Board of HCU Network America, an advocacy organization she founded in 2016 that is dedicated to supporting the needs of those impacted by the rare genetic condition homocystinuria (HCU) and related disorders. Ms. McGlynn served as a Director of Air Products & Chemicals Inc. since February 1, 2005 until November 23, 2020. She had been an Independent Director of Amicus Therapeutics, Inc. since October 2009 until April 27, 2026. She has been a Director of International AIDS Vaccine Initiative, Inc., since July 2010. She had been a Director of Vertex Pharmaceuticals Incorporated since May 2011 until May 17, 2023. In addition to her corporate experience, Ms. McGlynn has served as a Board Member for several non-profit organizations, including Hilleman Institute for Developing World Vaccine Research, Gavi, the Vaccine Alliance, the Biotechnology Innovation Organization (BIO) and Life Science Cares Philadelphia. She is a Director of Orphan Technologies Ltd. She served as a Director at Quidel Corp. She served as a Member of the Global Alliance for Vaccine Immunization (GAVI) Board. Former President at Merck Inc. Ms. McGlynn holds an MBA in Marketing from State University Of New York at Buffalo in 1983 and BS in Pharmacy from State University of New York At Buffalo in 1982 and an Honorary Doctorate from the State University of New York at Buffalo.

Positions